(Q35565658)

English

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?

scientific article published on 11 October 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? (English)

1 reference

Europe PubMed Central

8 August 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

2

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

8 August 2017

3

object named as

Susan O'Brien

1 reference

Europe PubMed Central

8 August 2017

1

object named as

Elias Jabbour

1 reference

Europe PubMed Central

8 August 2017

7

object named as

Mary Beth Rios

1 reference

Europe PubMed Central

8 August 2017

Guillermo Garcia-Manero

6

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

8 August 2017

Jorge Eduardo Cortes

8

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

8 August 2017

4

object named as

Jianqin Shan

1 reference

Europe PubMed Central

8 August 2017

author name string

Alfonso Quintás-Cardama

5

1 reference

Europe PubMed Central

8 August 2017

language of work or name

0 references

publication date

11 October 2011

1 reference

Europe PubMed Central

8 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

8 August 2017

29

1 reference

Europe PubMed Central

8 August 2017

4260-4265

1 reference

Europe PubMed Central

8 August 2017

32

1 reference

Europe PubMed Central

8 August 2017

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

27 July 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3221527

26 September 2018

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21990394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.36.0693

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35565658&oldid=1858462852"